Navigation Links
OncoGenex Reports Second Quarter Financial Results
Date:8/5/2010

g. OGX-427 is designed to reduce levels of Hsp27, a heat shock protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy, and radiation therapy. Results demonstrated that OGX-427 was safe and well tolerated as monotherapy, as well as in combination with docetaxel. In addition, when OGX-427 was used as a single agent there were declines in circulating tumor cells in patients at all doses and in all diseases evaluated, as well as evidence of reduction in tumor markers in prostate and ovarian cancer. - Partnering discussions and assessment of other opportunities to expand the development plan into additional randomized Phase 2 trials will continue. - A Phase 1 trial in bladder cancer is currently underway. - A randomized Phase 2 trial in CRPC is expected to initiate later this year.

Financial Results

Under our Collaboration Agreement with Teva relating to our contribution to the custirsen Phase 3 development plan, we earned Collaboration Revenues of $1.7 million and $6.4 million, respectively, for the three and six months ended June 30, 2010, compared to no revenues in the corresponding periods of 2009. Of the revenues in the second quarter, $362 thousand is reimbursable from Teva on a cash basis and is included on the Company's balance sheet as amounts receivable at June 30, 2010. As of June 30, 2010, $24.1 million of the upfront payment received from Teva was included on the Company's balance sheet as deferred collaboration revenue which we are amortizing over the expected performance period of our del
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
3. OncoGenex Reports First Quarter Financial Results
4. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
5. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
6. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
7. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
8. OncoGenex Reports Third Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Cheshire Cat: Can a particle be separated from its ... Communications , published the results of the first Cheshire ... conducted by Chapman University in Orange, CA, and Vienna ... a cat without a grin," thought Alice in Wonderland, ... curious thing I ever saw in my life!" Alice,s ...
(Date:7/29/2014)... YORK , July 29, 2014  Pomerantz LLP ... Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On July 29, 2014, Impax Laboratories, ...
(Date:7/29/2014)... Calif. , July 29, 2014 /PRNewswire-iReach/ -- ... agreement with FORMA Therapeutics, Inc., to provide access ... proprietary fragment-based lead discovery platform for novel small ... excited about the opportunity to work with FORMA ... of epigenetics and protein homeostasis. FORMA Therapeutics, decision ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in ... solutions for hospitals, will be exhibiting at booth #209 ... Conference & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... making hospitals cleaner, reducing infection risk and saving millions ... cycle. Staff will be available at booth #209 ...
Breaking Biology Technology:The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... DJO Incorporated,(NYSE: DJO ), a global provider of ... reported that on August 9, 2007,the U.S. Federal Trade ... the Hart-Scott-Rodino Antitrust Improvements Act of,1976, as amended, for ... Therapeutics, Inc. ("ReAble"). On July 16, 2007, DJO ...
... Valeant Pharmaceuticals ... ... Biosciences,Inc. (Pink Sheets: ARDC) today announced that it has received the ... (NYSE: VRX ). In December 2006, Ardea Biosciences entered ...
... Shareholder Support for Vermed Sale, SAN DIEGO, Aug. ... innovator and leader of,impedance cardiography (ICG) technology, today announced ... progressing well with over 50%,of the necessary shareholder votes ... the Vermed sale. The ratio of votes,received is running ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. 2CardioDynamics Provides 2007 Shareholder Meeting Update 2CardioDynamics Provides 2007 Shareholder Meeting Update 3
(Date:7/29/2014)... cell, including sperm, bacteria and algae, propel themselves ... about one-hundredth of a millimetre long, function like ... shorter structures called cilia are found on the ... such as moving liquids over the cell. ... transport mucus and expel pathogens from our airways, ...
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... cancer has shown considerable promise in early clinical trials ... drugs. Chemists and biologists at ... Sloan-Kettering Cancer Center, have created a new drug to ... as castration-resistant prostate cancer, or CRPC. Also referred to ...
... of drug-resistant bacteria, called multidrug-resistant gram-negative (MDRGN) ... common antimicrobial-resistant infections in long-term care facilities, ... at Hebrew SeniorLife,s Institute for Aging Research., ... of the main reservoirs of antimicrobial-resistant bacteria. ...
... /PRNewswire-Asia/ -- Futronic Technology Company,Limited, a global provider of ... of FS90 USB2.0 Mini Fingerprint,Scanner. , ... deliver high quality image,in a very small form factor. ... and just,slightly larger than one half of Futronic FS80 ...
Cached Biology News:New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Study finds multidrug-resistant gram-negative bacteria high in long-term care 2Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner 2
HOXC11 Antibody...
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Biology Products: